 |
市場調查報告書
商品編碼
2084636
緩解疾病抗風濕藥（DMARD）市場：依藥物類型、給藥途徑、適應症、通路及地區分類Disease-Modifying Antirheumatic Drug (DMARD) Market, By Drug Type, By Route of Administration, By Indication, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
預計到 2026 年，緩解疾病抗風濕藥物 (DMARD) 市場規模將達到 237.2 億美元，到 2033 年將達到 301.8 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 3.5%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 237.2億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 3.50% | 2033年市場規模預測： | 301.8億美元 |
緩解疾病抗風濕藥（DMARDs）可以治療疾病的根本病因並減輕發炎。它們用於治療類風濕性關節炎、乾癬性關節炎、全身性紅斑性狼瘡和僵直性脊椎炎自體免疫疾病。在這些疾病中，原本用來抵抗感染的免疫系統會攻擊自身健康的組織。 DMARDs可改善疼痛、僵硬和腫脹等症狀，但其全部療效可能需要數週甚至數月才能顯現。 DMARDs有多種類型，其作用機制略有不同。主要分為三大類：合成DMARDs（sDMARDs）、標靶合成DMARDs和生物DMARDs（bDMARDs）。
市場動態
全球緩解疾病抗風濕藥（DMARD）市場的主要企業正致力於新產品上市和擴大獲批範圍，預計將推動預測期內的市場成長。例如，2018年1月，領先的學名藥公司之一Hetero在印度推出了第四款生物相似藥－Adalimumab），商品名為Mabura。 Mabura是一種針對人類腫瘤壞死因子（TNF）的抗發炎生物製藥，適用於治療類風濕性關節炎和其他自體免疫疾病，例如乾癬性關節炎僵直性脊椎炎、克隆氏症和潰瘍性大腸炎。此外，2020年9月，美國跨國製藥和生物技術公司輝瑞宣布，美國食品藥物管理局（FDA）已批准XELJANZ（託法替尼）用於治療2歲及以上患有活動性多關節型幼年特發性關節炎（pcJIA）的兒童和青少年。該藥有兩種劑型獲批，分別為片劑和口服溶液，劑量根據體重決定。這次核准後，XELJANZ成為美國首個也是目前唯一獲準用於治療pcJIA的Janus激酶（JAK）抑制劑。
本次調查的主要特點。
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據以下參數介紹了全球緩解疾病抗風濕藥物（DMARDs）市場主要參與者的概況：公司亮點、產品系列、關鍵亮點、財務績效和策略。
- 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
- 這份《全球緩解疾病抗風濕藥物（DMARDs）市場》報告的目標相關人員包括經銷商、供應商、產品製造商、分銷商、新參與企業和金融分析師等行業利益相關者。
- 相關人員可以透過利用分析全球緩解疾病抗風濕藥物 (DMARD) 市場中使用的各種策略矩陣來簡化決策過程。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 市場機遇
- 影響分析
- 市場趨勢
- 主要進展
- 產品核准
- 合作關係、併購
- 監理情勢
- PEST分析
- 波特五力分析
- 流行病學
- 穩健的管道分析
第4章 全球緩解疾病抗風濕藥物（DMARD）市場：依藥物類型分類，2021-2033年
- 合成（sDMARD）
- 標靶合成DMARDs（tsDMARDs）
- 生物製劑DMARDs（bDMARDs）
- 其他
第5章 全球緩解疾病抗風濕藥物（DMARD）市場：依給藥途徑分類，2021-2033年
- 口服
- 腸外
- 其他
第6章 全球緩解疾病抗風濕藥物（DMARD）市場：依適應症分類，2021-2033年
- 類風濕性關節炎
- 僵直性脊椎炎
- 乾癬性關節炎
- 全身性紅斑性狼瘡
- 其他
第7章 全球緩解疾病抗風濕藥物（DMARD）市場：依通路分類，2021-2033年
- 醫院藥房
- 零售藥房
- 網路藥房
第8章 全球緩解疾病抗風濕藥物（DMARD）市場：按地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第9章 競爭情勢
- 熱圖分析
- 市佔率分析
- 公司簡介
- Sanofi
- Pfizer
- F. Hoffman-La Roche AG
- Johnson & Johnson
- AbbVie Inc.
- Eli Lilly & Company
- Amgen Inc.
- Swedish Orphan Biovitrum AB
- Bristol-Myers Squibb Company
- UCB SA
- Gilead Sciences, Inc.
- Cumberland Pharmaceuticals Inc.
- 分析師意見
第10章
- 參考
- 調查方法
- 關於本公司
簡介目錄
Product Code: CMI5185
Disease-Modifying Antirheumatic Drug (DMARD) Market is estimated to be valued at USD 23.72 Bn in 2026 and is expected to reach USD 30.18 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 23.72 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.50% | 2033 Value Projection: | USD 30.18 Bn |
Disease-modifying anti-rheumatic drugs (DMARDs) can treat the underlying cause of condition and reduce inflammation. They are given to people with autoimmune conditions, such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis and others. These are conditions where the immune system, which normally fights infection, attacks the body's own healthy tissues. DMARDs can improve symptoms such as pain, stiffness and swelling, but they may take a few weeks or even months to fully take effect. There are different types of DMARDs, and they work in slightly different ways. The three main types are: synthetic (sDMARD), targeted synthetic DMARDs, biological DMARDs (bDMARD) and others
Market Dynamics
Key players operating in the global disease-modifying anti-rheumatic drugs (DMARDs) market are focusing on increasing product launches and product approvals which is expected to drive the market growth during the forecast period. For instance, in January 2018, Hetero, one of the leading generic pharmaceutical companies launched its fourth biosimilar drug 'Adalimumab' under the brand name 'Mabura' in India. Mabura is an anti-inflammatory biologic medication specific for human tumor necrosis factor (TNF). It is indicated for the treatment of rheumatoid arthritis and other auto-immune disorders such as psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. Moreover, in September 2020, Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation announced that the U.S. Food and Drug Administration (FDA) approved XELJANZ (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight. This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global disease-modifying anti-rheumatic drugs (DMARDs) market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Sanofi., Pfizer, F. Hoffman-La Roche AG, Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc., Swedish Orphan Biovitrum AB, Bristol-Myers Squibb Company, UCB S.A., Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global disease-modifying anti-rheumatic drugs (DMARDs) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global disease-modifying anti-rheumatic drugs (DMARDs) market
Market Segmentation
- By Drug Type (Revenue, USD Bn, 2021-2033)
- Synthetic (sDMARD)
- Conventional synthetic (csDMARDs)
- Methotrexate
- Sulfasalazine
- Leflunomide
- Hydroxychloroquine
- Gold Salts
- Targeted synthetic DMARDs (tsDMARDs)
- Biological DMARDs (bDMARD)
- Original DMARDs (boDMARDs)
- Biosimilar DMARDs (bsDMARDs)
- Primary
- Secondary
- Tertiary
- Others
- By Route of Administration (Revenue, USD Bn, 2021-2033)
- Oral
- Parenteral
- Others
- By Indication (Revenue, USD Bn, 2021-2033)
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Systemic Lupus Erythematosus
- Others
- By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Pfizer
- Hoffman-La Roche AG
- Johnson & Johnson
- AbbVie Inc.
- Eli Lilly & Company
- Amgen Inc.
- Swedish Orphan Biovitrum AB
- Bristol-Myers Squibb Company
- UCB S.A.
- Gilead Sciences, Inc.
- Cumberland Pharmaceuticals Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Drug Type, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Synthetic (sDMARD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Conventional synthetic (csDMARDs)
- Methotrexate
- Sulfasalazine
- Leflunomide
- Hydroxychloroquine
- Gold Salts
- Targeted synthetic DMARDs (tsDMARDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Biological DMARDs (bDMARD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Original DMARDs (boDMARDs)
- Biosimilar DMARDs (bsDMARDs)
- Primary
- Secondary
- Tertiary
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
5. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Route of Administration, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
6. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Indication, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Psoriatic Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Systemic Lupus Erythematosus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
7. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Distribution Channel, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
8. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Region, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Sanofi
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- F. Hoffman-La Roche AG
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Eli Lilly & Company
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Swedish Orphan Biovitrum AB
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- UCB S.A.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cumberland Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Sanofi
- Analyst Views
10. Section
- References
- Research Methodology
- About Us
